Quotient Sciences, a CRDMO (Contract Research, Development and Manufacturing Organization), has extended its commercial supply partnership with Ipsen, a global biopharma company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide. This collaboration reinforces Quotient Sciences’ support for the manufacture of niche and smaller volume commercial products. Sohonos (Palovarotene), approved by the FDA in 20...